Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Norman

Showing results (11-20 of 84) with videos related to

Pageof 9
Sort By:
Pharmaceutical Patent Analyst|March 20, 2018
Brexit and UK market exclusivitiesPeter Norman
Idrugs : the Investigational Drugs Journal|February 8, 2007
Nociception: Taking the Pain out of Drug Discovery. 28 November 2006, London, UKPeter Norman
Expert Opinion on Investigational Drugs|August 22, 2013
New dual-acting bronchodilator treatments for COPD, muscarinic antagonists and β2 agonists in combination or combined into a single moleculePeter Norman
Expert Opinion on Therapeutic Patents|October 24, 2013
Highly selective Janus kinase 3 inhibitors based on a pyrrolo[2,3-d]pyrimidine scaffold: evaluation of WO2013085802Peter Norman
Expert Opinion on Therapeutic Patents|November 29, 2013
Evaluation of WO2013136076: two crystalline forms of the phosphatidylinositol 3-kinase-δ inhibitor RV-1729Peter Norman
Expert Opinion on Therapeutic Patents|October 19, 2014
Evaluation of WO2014075392 and WO2014075393, Merck's first PI3Kδ inhibitor filingsPeter Norman
Expert Opinion on Therapeutic Patents|May 15, 2015
Evaluation of US20150011555. An inhaled IP receptor agonist for the treatment of pulmonary arterial hypertensionPeter Norman
Expert Opinion on Therapeutic Patents|September 14, 2012
Selective JAK1 inhibitor and selective Tyk2 inhibitor patentsPeter Norman
Expert Opinion on Therapeutic Patents|January 7, 2014
Evaluation of WO2013116562A, an orally active PI3Kδ inhibitor for the treatment of asthmaPeter Norman
Expert Opinion on Therapeutic Patents|July 21, 2012
Evaluation of WO2012037132 - a novel scaffold for selective JAK1 inhibitionPeter Norman
Pageof 9

Showing results (11-20 of 84) with videos related to

Sort By:
Pageof 9
Pharmaceutical Patent Analyst|March 20, 2018
Brexit and UK market exclusivitiesPeter Norman
Idrugs : the Investigational Drugs Journal|February 8, 2007
Nociception: Taking the Pain out of Drug Discovery. 28 November 2006, London, UKPeter Norman
Expert Opinion on Investigational Drugs|August 22, 2013
New dual-acting bronchodilator treatments for COPD, muscarinic antagonists and β2 agonists in combination or combined into a single moleculePeter Norman
Expert Opinion on Therapeutic Patents|October 24, 2013
Highly selective Janus kinase 3 inhibitors based on a pyrrolo[2,3-d]pyrimidine scaffold: evaluation of WO2013085802Peter Norman
Expert Opinion on Therapeutic Patents|November 29, 2013
Evaluation of WO2013136076: two crystalline forms of the phosphatidylinositol 3-kinase-δ inhibitor RV-1729Peter Norman
Expert Opinion on Therapeutic Patents|October 19, 2014
Evaluation of WO2014075392 and WO2014075393, Merck's first PI3Kδ inhibitor filingsPeter Norman
Expert Opinion on Therapeutic Patents|May 15, 2015
Evaluation of US20150011555. An inhaled IP receptor agonist for the treatment of pulmonary arterial hypertensionPeter Norman
Expert Opinion on Therapeutic Patents|September 14, 2012
Selective JAK1 inhibitor and selective Tyk2 inhibitor patentsPeter Norman
Expert Opinion on Therapeutic Patents|January 7, 2014
Evaluation of WO2013116562A, an orally active PI3Kδ inhibitor for the treatment of asthmaPeter Norman
Expert Opinion on Therapeutic Patents|July 21, 2012
Evaluation of WO2012037132 - a novel scaffold for selective JAK1 inhibitionPeter Norman
Pageof 9